Rapid field-deployable detection of SARS-CoV-2 virus
Assignee
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
Inventors
Melanie Ott, Parinaz Fozouni, Jennifer A. Doudna, Daniel A. Fletcher, David Savage, Emeric Charles, Sungmin Son, Gagandeep Renuka Kumar, Neil Switz
Abstract
The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with SARS-CoV-2 crRNA guide RNAs to detect and quantify the presence of SARS-CoV-2 RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose SARS-CoV-2 infection, quantify the concentration of SARS-CoV-2 RNA present in a sample, identify the presence of different SARS-CoV-2 splice variants, subtypes, or mutations, and to monitor reactivation of SARS-CoV-2 transcription.
CPC Classifications
Filing Date
2021-03-18
Application No.
17206020
Claims
57